Iktos is at the forefront of revolutionizing drug discovery through the integration of advanced technologies such as Generative AI, retrosynthesis, and robotics. Their flagship platform, Makya, utilizes Generative AI to design novel and diverse molecules that are not only innovative but also synthetically accessible, ensuring a higher likelihood of success in drug development. Following this, the Spaya platform employs AI-driven retrosynthesis to identify optimal synthetic routes, converting target compounds into commercially available starting materials efficiently. This data-driven approach enhances the synthesis process, making it adaptable and compatible with Iktos's robotic systems, thereby streamlining the overall drug discovery workflow.

The company's Autonomous Lab further automates the synthesis of compounds, facilitating high-throughput and AI-driven processes that encompass the entire Design-Make-Test-Analysis (DMTA) cycle. This integration allows for continuous feedback and iterative optimization, significantly reducing the time required to identify viable drug candidates to under two years. By leveraging these cutting-edge technologies, Iktos not only accelerates the development of new treatments but also enhances collaboration with pharmaceutical and biotech companies, showcasing their commitment to innovation in drug discovery.

France

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.

Please visit our webpage to know more about our products and offerings 
https://iktos.ai/products/

Iktos

Company Details